

*Getting Up Off The Mat*

## Alteon Sees New Life For Alagebrium After Merger

By **Brady Huggett**  
 Managing Editor


When Noah Berkowitz and **HaptoGuard Inc.** were approached about a possible merger with flailing **Alteon Inc.**, they had their doubts.

"We were concerned about two things," Berkowitz told *BioWorld Financial Watch*. "Science, and the brand of the company in general. We understood it was a company that had been around for 18 years or so, that it had not produced a successful drug and that it had not proved its technology. That was compounded by our assumption, when we heard about it, that alagebrium was dead."

If alagebrium, an advanced glycostatin end product (A.G.E.) Crosslink Breaker, wasn't dead, it was at least lying on its back and gasping for breath, having sustained a brutal pounding in the clinic. But Berkowitz pulled the compound to its feet, peered in and found something he liked.

HaptoGuard's management felt alagebrium "could be in advanced Phase II studies in a short period of time and be not far from an NDA," he said. "When we looked at Alteon, we said, Wow. Look at how little this company is selling at today. It's so severely undervalued, we should consider it."

They did, and last month shareholders approved a stock merger valued at \$8.8 million, which made former chairman, president and CEO of Alteon, Kenneth Moch, the combined company's chairman, and established Berkowitz as president and CEO. Now all Berkowitz has to do is convince investors he's not shopping another biotech tomato



can, hyping a compound that will go back into late-stage work to again get knocked out.

### Alteon's Uneven Path

Alteon first was known for pimagedine, its initial A.G.E. Crosslink Breaker. A.G.E.'s, when formed and cross-linked, can cause a loss of flexibility and function in body tissues,

*See Alteon, Page 2*

10 BIGGEST U.S. GAINERS FOR THE WEEK			
(By Percent)		(By Dollars)	
Advancis Pharma	16.22	Theravance	1.94
Emisphere Techno	16.00	Advancis Pharma	1.58
Palatin Technologies	15.79	Emisphere Techno	1.20
Immunicon	15.38	Salix Pharma	0.72
Avax Technologies	15.38	New River Pharma	0.67
MacroChem	15.34	Santarus	0.67
Carrington Labs	13.67	Immunicon	0.63
Caliper Life Sci	13.50	Caliper Life Sci	0.57
Sequenom	12.64	Immtech International	0.55
Santarus	11.54	Integra LifeSci	0.52

10 BIGGEST U.S. LOSERS FOR THE WEEK			
(By Percent)		(By Dollars)	
icagen	-76.65	Cephalon	-9.65
Cellegy Pharma	-30.77	Amylin Pharma	-6.57
OraSure Techno	-30.20	Celgene	-5.42
DOV Pharma	-25.76	ImClone Systems	-4.95
Ortec Intl.	-21.21	Amgen	-4.01
Matritech	-21.05	Invitrogen	-3.75
BioCryst Pharma	-20.46	icagen	-3.25
Cepheid	-19.13	Genzyme	-3.03
CEL-SCI	-18.99	MannKind Corp	-2.91
Monogram Biosci	-18.39	OraSure Techno	-2.83

**INSIDE:** CLINICAL TRIALS UPDATE: JULY 2006 ..... 3  
 NON-U.S. CLINICAL TRIALS; FDA ACTIONS..... 9, 13



## Alteon

*Continued from Page 1*

organs and vessels. By the close of 1996, pimagedine was in two pivotal trials for diabetic kidney disease – ACTION I in Type I diabetics with overt nephropathy and ACTION II in Type II diabetics. Alteon expanded into a pivotal study in 1997 a Phase II trial of pimagedine in diabetic patients with end-stage renal disease, and later that year it signed heavy hitter **Genentech Inc.** as partner in a deal that had a potential of \$200 million.

But as often is the case in biotech, things went sour. In the spring of 1998, Alteon lost about 50 percent of its stock value, falling to \$4.94, after an External Safety Monitoring Committee recommended ACTION II be stopped due to side effects. Days later, the FDA agreed with the panel, and the trial was officially ended.

ACTION I missed its primary endpoint in a preliminary analysis, reported in November 1998, causing Genentech to back out of their deal months later. The trial was officially closed in 1999, and the company's stock had slid to less than \$1.

But Alteon reloaded. The company began focusing on alagebrium, also called ALT-711, and advanced it in the clinic. However, misses in two Phase IIb hypertension trials in summer 2003 reduced the stock back to less than \$2. While the firm blamed a high placebo rate, a confirmatory Phase IIb study didn't pan out, either. Alteon briefly looked at erectile dysfunction in diabetics, noting the successes of Viagra and Cialis, but a Phase IIa trial there fizzled, too, after the FDA placed it on hold in 2005 because of certain rat toxicity data. (Earlier this year, the firm said it will discontinue development of alagebrium in ED, and withdrew its investigational new drug application in that indication.)

All of that left Alteon with no analyst coverage and a stock price trading at below 30 cents for most of 2006; its shares (AMEX:ALT) closed at 15 cents Friday. In mid-July it had about \$3 million in cash. This is what Berkowitz must revive.

## Fighting Back

His first step is explaining how Alteon is different from, say, **Intrabiotics Pharmaceuticals Inc.**, which developed its product iseganan for mucositis associated with chemotherapy, only to see it fail in Phase III. The compound was repositioned against ventilator-associated pneumonia, but safety concerns derailed it in another pivotal trial, the study was stopped, and the company discontinued operations in 2005. That was an investor's nightmare.

To understand why alagebrium still has life, one must look at Alteon's whole history, Berkowitz said. While he noted he now is "playing Monday-morning quarterback, and doing so cautiously," since he was not with Alteon at the time, Berkowitz said early work with alagebrium always showed "stronger data for heart failure than hypertension" and there was positive nephropathy data, too. But a business decision had to be made and what Alteon management knew at the time was that the hypertension market was massive, most thought an approval in heart failure was best reached via a label for hypertension, and the FDA had not established well-defined, non-event-driven endpoints for heart failure.

Throw in that Alteon had been badly burned by nephropathy before, with pimagedine, and Alteon made a "reasoned, not capricious" call to chase hypertension, Berkowitz said.

That didn't work out as planned, but with Berkowitz as new CEO, the company is reconsidering its original data. They approached key opinion leaders in heart failure and nephropathy and discussed alagebrium in those indications. Those leaders "breathed a sigh of relief," Berkowitz said, and congratulated them on finally following the science.

While the clinical blow-ups have scared off investors, the failures also are "a blessing in disguise" for heart failure work, Berkowitz said, "because nothing would satisfy a

*See Alteon, Page 8*

BioWORLD® FINANCIAL WATCH is published every Monday by the BioWorld® Publishing Group, a division of Thomson BioWorld®, 3525 Piedmont Road, Building Six, Suite 400, Atlanta, GA 30305. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. BioWORLD® and BioWORLD® FINANCIAL WATCH are trademarks of Thomson BioWorld®. Copyright © 2006 Thomson BioWorld®. All Rights Reserved. No part of this publication may be reproduced without the written consent of Thomson BioWorld®. (GST Registration Number R128870672)

**ATLANTA NEWSROOM:** Managing Editor: **Brady Huggett**.  
Database Editor: **Jim Shrine**.  
Editorial Coordinator: **Kay Torrance**.

**WEST COAST BUREAU:** Editor: **Randall Osborne**.

**BUSINESS OFFICE:** Vice President/Group Publisher: **Donald R. Johnston**.  
Senior Production Editor: **Ann Duncan**  
Marketing Manager: **Chris Walker**. Account Representative: **Bob Sobel**.

**DISPLAY ADVERTISING:** For ad rates and information, please call **Stephen Vance** at (404) 262-5511 or e-mail at [stephen.vance@thomson.com](mailto:stephen.vance@thomson.com).

**REPRINTS:** For photocopy rights or reprints, please call our reprints department at (404) 262-5479.

### SUBSCRIBER INFORMATION

Please call **(800) 688-2421** to subscribe or if you have fax transmission problems. Outside U.S. and Canada, call **(404) 262-5476**. Our customer service hours are 8:30 a.m. to 6:00 p.m. EST.

### EDITORIAL

Brady Huggett **(404) 262-5408**  
Randall Osborne, **(415) 384-0872**  
Fax: **(404) 814-0759**  
Publisher: Donald R. Johnston  
**(404) 262-5439**

Internet: <http://www.bioworld.com>

**THOMSON**



<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>Threshold Pharmaceuticals Inc. (THLD)</b>	TH-070	lonidamine; an indazole-3-carboxylic acid	Benign prostatic hyperplasia	Phase II trial did not demonstrate a statistically significant dose response, and Phase III did not produce symptomatic improvement vs. placebo; development is being discontinued (7/17)
<b>TissueGene Inc.*</b>	TG-C	Cell-mediated gene therapy delivering TGF-beta	Degenerative joint diseases	Began Phase I trial to evaluate safety in patients who have had total knee arthroplasty (7/24)

**Notes:**

\* Privately held.

BLA = Biologics license application; FDA = Food and Drug Administration; IND = Investigational new drug application; NDA = New drug application; SPA = Special protocol assessment.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; TEL = Tel Aviv Stock Exchange.

**Alteon**

*Continued from Page 2*

cardiologist more than a drug that can improve ventricular filling and compliance in patients with heart failure, but not carry the side effects of hemodynamic instability." Alteon already has data showing the drug doesn't affect blood pressure – the failed trials produced useful data there.

Also, the heart failure market for pharmaceuticals now is growing, and the FDA has shown a willingness to consider heart failure drugs on exercise tolerance endpoints – both positive changes since Alteon first considered alagebrium.

So here sits Alteon: Although not everything it has done has delivered positive news, it does have an impressive amount of clinical work behind it, and two Phase II trials of alagebrium have shown relevant activity in diastolic heart failure. It recently said the Juvenile Diabetes Research Foundation would fund a Phase II study in nephropathy in Type I diabetics.

From the HaptoGuard merger, the company also has ALT-2074 – a glutathione peroxidase mimetic – in myocardial injury in diabetics undergoing angioplasty or similar interventions. Phase II data are expected around the end of the year.

Still, even with two clinical products, a new CEO and management better suited to drive pharmaceutical devel-

opment, the company has its work cut out for it. The Motley Fool in June named Alteon one of its 10 worst stocks – it has provided a negative 98.6 percent return to investors since 1996 – and David Trainer, president of New Constructs LLC, an independent research firm in Nashville, Tenn., gives Alteon the worst rating his firm uses: "very dangerous."

"Investment is a game of buying and selling expectations," Trainer told *BioWorld Financial Watch*. "The bar for this stock is already set too high.

"There are roughly 3,000 stocks that Americans can choose from, and we cover all of them," he said. "There are many other better options out there than what Alteon provides. The valuation already considers that the management implies they will be much more successful than they have in the past."

The final sentiment Berkowitz would not argue with – he does expect better things ahead. How can others be convinced?

"You don't need insider information to review the dozens of articles that have been published on [alagebrium] in preclinical models," he said, and investors would be putting money into "a company that has a safety database in cardiovascular disease of more than 1,000 patients," and one that has a plan to file for heart failure in "several years."

"It's not easy" becoming CEO of a company with a stock price so low, he conceded, "but when you have something you believe in, you go for it." ■

## Non-U.S. Clinical Trials And Regulatory Actions: July 2006

<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>AUTOIMMUNE</b>				
<b>Aspreva Pharmaceuticals Corp.</b> (Canada; ASPV) and Hoffmann-La Roche Inc.	CellCept	Mycophenolate mofetil; an immunosuppressant	Lupus nephritis	The product was approved in Malaysia (7/19)
<b>Centocor Inc.</b> (unit of Johnson & Johnson)	Remicade (FDA-approved)	Infliximab; monoclonal antibody that targets tumor necrosis factor-alpha	Psoriatic arthritis	The label was expanded in Europe to include treatment of active and progressive PA in those intolerant to or unable to take methotrexate (7/26)
<b>Genentech Inc.</b> (NYSE:DNA) and <b>Biogen Idec Inc.</b> (BIIB)	MabThera (Rituxan; FDA-approved)	Rituximab; antibody that targets and selectively depletes CD20-positive B cells	Rheumatoid arthritis	Partner F. Hoffmann-La Roche Ltd. gained European approval of the drug for use with methotrexate in treating RA (7/11)
<b>CANCER</b>				
<b>Abraxis BioScience Inc.</b> (ABBI)	Abraxane (FDA-approved)	Paclitaxel protein-bound particles for injection; albumin-bound	Cancers	Partner Taiho Pharmaceutical Co. Ltd. began a Phase I trial in Japan (7/13)
<b>Aida Pharmaceuticals Inc.</b> (China; OTC BB:AIDA)	Rh-Apo2L	Apoptotic, gene therapy agent	Cancers	Phase I trial in 20 advanced patients in China demonstrated encouraging antitumor activity (7/27)
<b>CuraGen Corp.</b> (CRGN) and <b>TopoTarget A/S</b> (Denmark; CSE:TOPO)	PXDI01	Small-molecule histone deacetylase inhibitor	Inoperable hepatocellular cancer	Began Phase I/II trial in Hong Kong to evaluate safety and potential efficacy; the trial is sponsored by the National Cancer Institute (7/14)
<b>Oncolytics Biotech Inc.</b> (ONCY)	Reolysin	Intratumorally delivered formulation of the human reovirus	Advanced cancers	Is starting Phase II trial in the UK to evaluate efficacy in combina- tion with low-dose radiation ther- apy (7/18)
<b>Oncolytics Biotech Inc.</b> (ONCY)	Reolysin	Intratumorally delivered formulation of the human reovirus	Advanced cancers	Began Phase Ib trial in the UK to evaluate the drug in combination with radiation therapy (7/10)

<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>Onyx Pharmaceuticals Inc.</b> (ONXX) and Bayer Pharmaceuticals Corp.	Nexavar (FDA-approved)	Sorafenib; oral RAF kinase and VEGF inhibitor	Advanced renal cell carcinoma	The drug was approved in Europe for treating those who failed prior interferon-alpha- or interleukin-2-based therapy or who can't take those therapies; Bayer has European marketing rights (7/24)
<b>OSI Pharmaceuticals Inc.</b> (OSIP)	Tarceva (FDA-approved)	Erlotinib; small-molecule HER1/EGFR inhibitor	Advanced pancreatic cancer	The EMEA denied the marketing application filed in Europe by OSI partner F. Hoffmann-La Roche Ltd., which sought approval as a first-line treatment with gemcitabine (7/28)
<b>Peplin Ltd.</b> (Australia; ASX:PEP)	PEP005 Topical	Agent designed to kill cancer cells and stimulate an immune response	Basal cell carcinoma	Phase IIa trial in Australia demonstrated safety, tolerability; higher doses produced the best results (7/17)
<b>YM BioSciences Inc.</b> (Canada; TSE:YM)	Nimotuzumab (TheraCIM)	Humanized anti-epidermal growth factor receptor monoclonal antibody	Head and neck cancer	The product was approved in India, where it will be marketed by Biocon Biopharmaceuticals Ltd. (7/20)

## CARDIOVASCULAR

<b>Biopure Corp.</b> (BPUR)	Hemopure	Oxygen therapeutic consisting of bovine hemoglobin	For use in surgery procedures	Filed MAA in the UK seeking approval for treatment of acutely anemic adult orthopedic surgery patients younger than 80 (7/11)
<b>Neose Technologies Inc.</b> (NTEC)	NE-180	Long-acting, GlycoPEG-ylated erythropoietin	Anemia	Phase I trial in Europe demonstrated tolerability; Neose is working with the FDA to lift clinical hold put on U.S. studies (7/11)
<b>PharmaMar SA</b> (Spain; subsidiary of Zeltia Group)	Yondelis	Trabectedin; ET-743; derived from the sea squirt Ecteinascidia turbinata	Soft-tissue sarcomas	Submitted MAA seeking approval in Europe in that indication (7/27)
<b>Pharming Group NV</b> (the Netherlands; Euronext:PHARM)	rhCIINH	Recombinant human C1 inhibitor	Hereditary angioedema	Submitted MAA seeking approval in Europe for treating acute attacks of HAE (7/21)
<b>Trigen Holdings AG*</b> (Germany)	TGN 255	Intravenous, synthetic direct thrombin inhibitor	For use as an anticoagulant	Phase II trial in 28 patients undergoing hemodialysis showed drug was well tolerated and demonstrated a dose response (7/17)

<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>CENTRAL NERVOUS SYSTEM</b>				
<b>Abiogen Pharma SpA*</b> (Italy)	ABIO 08/01	Non-addictive agent from new class, different from anxiolytic sedatives	Generalized anxiety disorders	Began a Phase II trial of the product in Austria (7/5)
<b>CeNeS Pharmaceuticals plc</b> (UK; AIM:CEN)	CNS 5161	Selective NMDA antagonist	Pain	Began Phase II trial to evaluate safety and efficacy in 75 diabetic neuropathy patients; and began Phase I/II trial to evaluate the drug in 24 patients with opioid-refractory cancer pain (7/13)
<b>DanioLabs Ltd.*</b> (UK)	DI06001 and DI06002	Novel combinations of established drugs	Parkinson's disease symptoms	Began Phase I trials in the UK in healthy volunteers; the products are being developed for drooling and excessive sweating, respectively (7/3)
<b>DIABETES</b>				
<b>Oramed Pharmaceuticals Inc.</b> (Israel; OTC BB:ORMP)	—	Soft gel insulin capsule	Diabetes	Is starting a Phase I trial in healthy volunteers in Israel (7/11)
<b>Phosphagenics Ltd.</b> (Australia; ASX:POH)	TPM-02/ Insulin	Insulin delivered by transdermal carrier	Diabetes	Began a Phase I trial in Australia to evaluate safety and tolerability in 20 healthy volunteers (7/24)
<b>INFECTION</b>				
<b>Crucell NV</b> (the Netherlands; CRXL)	Aerugen	Vaccine candidate	Pseudomonas aeruginosa infections	Development was suspended after Phase III trial in Europe failed to demonstrate efficacy in preventing P. aeruginosa infection in cystic fibrosis patients (7/18)
<b>Viral Genetics Inc.</b> (OTC BB: VRAL)	VG-V1	Thymus nuclear protein	HIV	137-patient trial in South Africa showed statistically significant reductions in viral load in 22% of patients (7/24)
<b>MISCELLANEOUS</b>				
<b>BioMimetic Therapeutics Inc.</b> (BMTI)	GEM OSI Bone Graft	Recombinant platelet-derived growth factor combined with a synthetic bone matrix	Fractures and bone fusions	Completed enrollment in pilot study in Canada and got approval to expand the study from 20 patients up to 60 (7/11)

<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>Cangene Corp.</b> (Canada; TSE:CNJ)	Accretropin	Recombinant human growth hormone	Short stature in children with growth hormone deficiency	The company filed NDA with the FDA, and the agency accepted the application for review (7/17)
<b>ConjuChem Biotechnologies Inc.</b> (Canada; TSE:CJB)	DAC:GRF	Chemically modified form of growth hormone-releasing factor	HIV lipodystrophy	Company put hold on program following a patient's death at a site in Argentina, in a Phase II trial (7/14)
<b>Debiopharm Group*</b> (Switzerland)	Sanvar	Synthetic octapeptide analogue of the somatostatin hormone	Esophageal variceal bleeding	Filed for approval of the product in France, the first step toward seeking approval across Europe (7/24)
<b>Insmed Inc.</b> (INSM)	iPlex (FDA-approved)	Composition of insulin-like growth factor-I and its primary binding protein, BP3	Children with severe primary IGF-I deficiency	European regulators validated marketing application; the EMEA will begin review of MAA (7/5)
<b>Pharmaxis Ltd.</b> (Australia; ASX:PXS)	Aridol	Mannitol formulation delivered via an inhalation device	Asthma	The company filed for approval in Switzerland (7/21)
<b>Progenics Pharmaceuticals Inc.</b> (PGNX) and Wyeth	MNTX	Intravenous form of methylalntrexone; agent designed to block peripheral opioid receptors	Postoperative ileus	The FDA granted fast-track status to the product; Phase III trials are being planned (7/17)
<b>Revotar Biopharmaceuticals AG*</b> (Germany)	Bimosiamose	Topical formulation of a pan-selectin antagonist	Inflammatory conditions	Phase I trial in 24 healthy subjects in Germany demonstrated safety and tolerability (7/26)
<b>Topigen Pharmaceuticals Inc.*</b> (Canada)	TPI-ASM8	Inhalation agent targeting the CCR3 receptor and IL-3, IL-5 and GM-CSF receptors	Allergic asthma	Phase II trial in 17 patients in Canada demonstrated protection in early and late-stage allergic responses (7/18)
<b>Y's Therapeutics Inc.*</b>	YSPSL	Molecule resulting from fusion of P-selectin glycoprotein ligand-I to human IgG1	Prevention of graft dysfunction	The EMEA granted orphan designation to the product for preventing graft dysfunction in kidney transplantation (7/20)

**Notes:**

\* Privately held.

MAA = Marketing authorization application; MRP = Mutual Recognition Procedure; EMEA = European Medicines Agency.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AIM = Alternative Investment Market; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

## FDA Submissions, Approvals And Other Actions: July 2006

<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>AUTOIMMUNE</b>				
<b>Abbott Laboratories</b>	Humira (FDA-approved)	Adalimumab; fully human antibody designed to block TNF-alpha	Ankylosing spondylitis	The FDA approved the drug for the additional indication of reducing signs and symptoms in those with active AS (7/31)
<b>CANCER</b>				
<b>Allos Therapeutics Inc.</b> (ALTH)	PDX	Pralatrexate; small-molecule inhibitor of dihydrofolate reductase	T-cell lymphoma	The FDA granted orphan designation to the product in that indication; Phase II trials are being planned (7/26)
<b>Enzon Pharmaceuticals Inc.</b> (ENZN)	Oncaspar (FDA-approved)	PEG-enhanced version of the naturally occurring enzyme L-asparaginase	Acute lymphoblastic leukemia	The FDA approved expanded use in ALL, for use as part of first-line chemotherapy regimen (7/25)
<b>GPC Biotech AG</b> (Germany; FSE:GPC) and <b>Pharmion Corp.</b> (PHRM)	Satraplatin	Oral platinum compound	Hormone-refractory prostate cancer	Submitted non-clinical section of rolling NDA, which seeks approval in combination with prednisone as a second-line therapy (7/12)
<b>Intracel Corp.*</b>	OncoVAX	Patient-specific tumor cell vaccine; immunotherapy	Stage II colon cancer	The FDA granted SPA for confirmatory pivotal Phase III trial that will include 560 patients (7/19)
<b>Onyx Pharmaceuticals Inc.</b> (ONXX) and Bayer Pharma- ceuticals Corp.	Nexavar (FDA-approved)	Sorafenib tablets; oral RAF kinase and VEGF inhibitor	Advanced melanoma	The FDA granted fast-track designation to the product in that indication, for which the Phase III PRISM combination trial is ongoing (7/20)
<b>CARDIOVASCULAR</b>				
<b>Corautus Genetics Inc.</b> (VEGF)	VEGF-2	Vascular endothelial growth factor-2 in the form of naked plasmid DNA	Severe angina	The FDA lifted the hold it placed on Phase IIb GENASIS trial in March; Corautus will analyze data for efficacy on 295 patients already treated (7/13)
<b>Encysive Pharmaceuticals Inc.</b> (ENCY)	Thelin	Sitaxsentan; small molecule designed to block endothelin	Pulmonary arterial hypertension	The FDA issued second approvable letter, saying one issue remained unresolved; it was not clear if additional trials will be needed (7/24)



<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>Pharming Group NV</b> (the Netherlands; Euronext:PHARM)	rhCIINH	Recombinant human CI inhibitor	Hereditary angioedema	The FDA granted fast-track designa- tion to the product in that indi- cation (7/28)

## CENTRAL NERVOUS SYSTEM

<b>Vernalis plc</b> (UK; VNLS) and <b>Endo Pharmaceuticals Inc.</b> (ENDP)	Frova (FDA-approved)	Frovatriptan; 5HT 1B/1D agonist	Menstrually related migraine	Endo submitted supplemental NDA to the FDA, seeking approval in that indication (7/19)
--	-------------------------	------------------------------------	------------------------------------	--

## INFECTION

<b>Gilead Sciences Inc.</b> (GILD) and Bristol-Myers Squibb Co.	Atripla	Once-daily, single tablet containing BMS' Sustiva and Gilead's Truvada (Viread and Emtriva)	HIV	The FDA approved the product for treating HIV infection in adults (7/12)
<b>MedImmune Inc.</b> (MEDI)	CAIV-T	Trivalent vaccine; next generation of FluMist; refrigerator-stable formulation	Influenza	Submitted supplemental BLA with FDA, seeking approval in children 12 to 59 months of age who do not have a history of wheezing or asthma (7/31)
<b>MedImmune Inc.</b> (MEDI)	CAIV-T	Trivalent vaccine; next generation of FluMist; refrigerator-stable formulation	Influenza	FDA response letter to BLA asked for clarification and additional information relating to data previ- ously submitted; the filing seeks approval for those 5 to 49 years of age (7/18)
<b>Nabi Bio- pharmaceuticals</b> (NABI)	Nabi-HB	Hepatitis B immune globulin; intravenous solution of human antibodies	Hepatitis B	An FDA advisory committee rec- ommend approval of product for preventing recurrence of hepatis- tis B after liver transplant; the BLA was filed in November 2002 (7/13)

## MISCELLANEOUS

<b>Adeza Biomedical Corp.</b> (ADZA)	Gestiva	Long-acting form of a naturally occurring progesterone	Prevention of preterm birth	The FDA accepted the NDA for filing (7/6); an FDA advisory panel will review the NDA Aug. 29 (7/18)
--	---------	--	--------------------------------	--

<b>Company* (Country; Symbol)</b>	<b>Product</b>	<b>Description</b>	<b>Indication</b>	<b>Status (Date)</b>
<b>Cellegy Pharmaceuticals Inc.</b> (OTC BB:CLGY)	Cellegesic	Nitroglycerin ointment	Anal fissures	The FDA issued an approvable letter that calls for an additional trial; an amended NDA was resubmitted to the FDA in April 2005 (7/10)
<b>Critical Therapeutics Inc.</b> (CRTX)	—	Controlled-release formulation of zileuton (Zyflo), a 5-lipoxygenase inhibitor	Asthma	The company filed an NDA with the FDA, seeking approval in that indication (7/31)
<b>ISTA Pharmaceuticals Inc.</b> (ISTA)	T-Pred	Fixed combination of tobramycin and prednisolone acetate	Inflammatory ocular conditions	Filed NDA with the FDA, seeking approval in cases where a corticosteroid is indicated and where there are infections or risks of infection (7/6)
<b>Nastech Pharmaceutical Co. Inc.</b> (NSTK)	—	Intranasal calcitonin-salmon spray	Osteoporosis	The FDA cited immunogenicity issues in issuing a not-approvable letter on the abbreviated NDA for the generic product (7/13)
<b>Shire plc</b> (UK; product from former Transkaryotic Therapies Inc.)	Elaprase	Enzyme-replacement therapy; a form of the lysosomal enzyme iduronate-2-sulfatase	Hunter syndrome (mucopolysaccharidosis II)	The FDA approved the product, the first approved treatment for the rare genetic disease (7/24)
<b>Valera Pharmaceuticals Inc.*</b>	Supprelin-LA	Implanted product that provides 12-month delivery of histrelin	Central precocious puberty	Submitted NDA seeking approval of the implant for treating the early onset of puberty (7/6)
<b>Y's Therapeutics Inc.*</b>	YSPSL	Molecule resulting from the fusion of P-selectin glycoprotein ligand-I to human IgG1	Prevention of graft dysfunction	The FDA granted orphan designation to the product for preventing graft dysfunction in kidney transplantation (7/20)

**Notes:**

\* Privately held.

BLA = Biologics license application; CMA = Continuous marketing application; FDA = Food and Drug Administration; IND = Investigational new drug application; NDA = New drug application; PDUFA = Prescription Drug User Fee Act; SPA = Special protocol assessment.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.

# BioWorld Stock Report For Public Biotechnology Companies

Company	Symbol	Close 8/4	Close 8/11	%Change WK	%Change YTD	Vol (000)	Company	Symbol	Close 8/4	Close 8/11	%Change WK	%Change YTD	Vol (000)
Astrom Biosci	ASTM	1.22	1.18	-3.28	-44.08	2368	Dendreon	DNDN	4.51	4.21	-6.65	-22.32	2652
Acadia Pharma	ACAD	6.19	5.26	-15.02	-46.60	1320	DepoMed	DEPO	4.31	3.97	-7.89	-33.83	1716
Accelrys	ACCL	6.28	6.28	0.00	-21.79	138	Digene	DIGE	41.24	46	11.54	57.70	4662
Access Pharma	ACCP	1.04	0.88	-15.38	-66.15	33	Discovery Labs	DSCO	1.73	1.62	-6.36	-75.78	1082
Acusphere	ACUS	2.85	2.5	-12.28	-53.18	1113	Discovery Partners	DPPI	2.7	2.83	4.81	6.79	414
Adolor	ADLR	25.74	24.46	-4.97	67.53	2351	Diversa	DVSA	9.24	8.65	-6.39	80.21	1170
Advanced Life Sci	ADLS	2.92	2.99	2.40	-23.72	90	DOR BioPharma	DORB	0.25	0.25	0.00	-7.41	454
Advancis Pharma	AVNC	2.99	4.57	52.84	231.16	2888	DOV Pharma	DOVP	1.32	0.98	-25.76	-93.32	6300
Aeolus Pharma	AOLS	0.88	0.85	-3.41	-10.53	5	Draxis Health	DRAX	4.5	4.7	4.44	8.55	183
AEterna Zentaris	AEZS	5.67	5.26	-7.23	3.14	41	DURECT	DRRX	3.73	3.66	-1.88	-27.81	1388
Affymetrix	AFFX	19.9	20.12	1.11	-57.86	6180	DUSA Pharma	DUSA	4.43	4.18	-5.64	-61.19	448
Albany Molecular	AMRI	9.39	9.23	-1.70	-24.03	638	Dyadic International	DIL	6.89	6.79	-1.45	239.50	429
Alexion Pharma	ALXN	34.3	32.08	-6.47	58.42	1593	Dyax	DYAX	3.05	2.75	-9.84	-47.82	305
Alkermes	ALKS	17.32	16.15	-6.76	-15.53	5159	Dynavax Techno	DVAX	4.03	4.34	7.69	3.09	149
Alliance Pharma	ALLP	0.11	0.12	9.09	33.33	242	Embrex	EMBX	9.52	9.7	1.89	-30.01	174
Allos Therapeutics	ALTH	3.88	3.75	-3.35	74.42	717	Emisphere Techno	EMIS	7.4	8.6	16.22	98.16	2152
Alnylam Pharma	ALNY	12.87	11.72	-8.94	-12.28	806	Encysive Pharma	ENCY	4.09	4.14	1.22	-47.46	18567
Alteon	ALT	0.19	0.16	-15.79	-11.11	2424	EntreMed	ENMD	1.52	1.45	-4.61	-25.26	514
Amgen	AMGN	70.92	66.91	-5.65	-15.15	35566	Enzo Biochem	ENZ	12.48	11.39	-8.73	-8.29	720
Amylin Pharma	AMLN	48.8	42.23	-13.46	5.79	14340	Enzon Pharma	ENZN	8.08	7.73	-4.33	4.46	3141
Anadys Pharma	ANDS	3.5	2.86	-18.29	-67.50	2371	EpiCept	EPCT	2.29	2.14	-6.55	-74.82	24
Anesiva	ANSV	7.4	6.85	-7.43	-30.10	64	EPIX Medical	EPIX	4.88	4.27	-12.50	5.69	574
Antigenics	AGEN	1.73	1.6	-7.51	-66.39	1303	EXACT Sciences	EXAS	1.95	1.72	-11.79	-22.17	236
Aphton	APHTQ	0.01	0.01	0.00	-97.06	1610	eXegenics	EXEG	0.4	0.39	-2.50	-4.88	175
Aradigm	ARDM	2.01	1.87	-6.97	-48.77	121	Exelixis	EXEL	9.08	7.91	-12.89	-16.03	2394
Arena Pharma	ARNA	10.5	10.23	-2.57	-28.01	2395	Favrille	FVRL	4.2	4.02	-4.29	-0.74	49
Ariad Pharma	ARIA	4.05	3.72	-8.15	-36.41	1662	Flamel Techno S.A.	FLML	16.89	16.99	0.59	-10.01	286
ARQule	ARQL	5.13	5.23	1.95	-14.54	489	Genatera	GENR	0.44	0.38	-13.64	-74.67	4996
Array BioPharma	ARRY	8.27	7.91	-4.35	12.84	912	Gene Logic	GLGC	1.32	1.44	9.09	-57.01	721
Aspreva	ASPV	23.83	23.63	-0.84	50.32	900	Genelabs Techno	GNLB	1.2	1.21	0.83	-34.59	226
AtheroGenics	AGIX	12.98	12.55	-3.31	-37.28	1704	Genentech	DNA	80.35	80.12	-0.29	-13.38	8801
Autolmmune	AIMM	1.11	1.06	-4.50	15.22	35	Genexx Biotech	GNBT	1.39	1.33	-4.32	60.24	6620
Auxilium Pharma	AUXL	7.94	7.76	-2.27	41.09	596	Genitope	GTOP	2.33	2.41	3.43	-69.69	2916
Avanir	AVNR	6.35	6.3	-0.79	-54.22	2127	Gen-Probe	GPRO	52.74	50.98	-3.34	4.49	1242
AVANT Immunoth	AVAN	1.56	1.46	-6.41	-22.34	350	Genta	GNTA	1.52	1.41	-7.24	-3.42	5194
Avax Technologies	AVXT	0.13	0.15	15.38	-40.00	44	GenVec	GNVC	1.25	1.2	-4.00	-27.27	656
AVI BioPharma	AVII	3.13	2.72	-13.10	-21.16	2418	Genzyme	GENZ	69.82	66.79	-4.34	-5.64	8617
Avigen	AVGN	5.53	5.09	-7.96	67.99	213	Geron	GERN	5.95	6.04	1.51	-29.85	1728
Axonyx	AXYX	0.88	0.86	-2.27	3.61	399	Gilead Sciences	GILD	62.07	61.86	-0.34	17.67	12821
BioCryst Pharma	BCRX	11.19	8.9	-20.46	-46.87	2975	GPC Biotech AG	GPCB	15.45	14.85	-3.88	20.44	4
Biogen Idec	BIIB	42.65	41.58	-2.51	-8.17	15354	GTC Biothera	GTCB	1.3	1.23	-5.38	-25.00	1373
BioMarin Pharma	BMRN	15.54	15.29	-1.61	41.84	2735	GTX	GTXI	8.95	8.54	-4.58	12.96	283
Biomira	BIOM	0.96	0.86	-10.42	-38.57	1015	Hana Bioscience	HNAB	8.1	7.2	-11.11	22.66	520
Biopure	BPUR	0.93	0.89	-4.30	14.10	910	Helix Biomedix	HXB	0.92	0.95	3.26	21.79	41
BioTime	BTIM	0.25	0.22	-12.00	-29.03	70	Hemisphere	HEB	2.13	2.13	0.00	-1.84	429
Boston Life Sci	BLSI	4.07	3.93	-3.44	76.23	58	Human Genome	HGSI	10.06	9.64	-4.17	12.62	11387
Bruker BioSciences	BRKR	6.28	6.25	-0.48	28.60	1185	icagen	ICGN	4.24	0.99	-76.65	-84.65	4250
Caliper Life Sci	CALP	4.17	4.74	13.67	-19.39	586	ICOS	ICOS	22.77	22.81	0.18	-17.44	3208
Cardiovascular Bio	CVBT	3.6	3.4	-5.56	-25.27	146	IDenix Pharma	IDIX	9.22	8.63	-6.40	-49.56	1067
Carrington Labs	CARN	3.13	3.61	15.34	-23.68	111	Idera Pharma	IDP	2.72	2.45	-9.93	-49.80	81
Celera Genomics	CARA	13.27	13.15	-0.90	19.98	3107	IDEXX Laboratories	IDXX	89.67	88.47	-1.34	22.91	654
Celgene	CELG	46.95	41.53	-11.54	28.18	25593	IDM Pharma	IDMI	2.5	2.75	10.00	5.77	36
Cell Genesys	CEGE	4.95	4.41	-10.91	-25.63	1092	illumina	ILMN	37.5	35.05	-6.53	148.58	4773
Cell Therapeutics	CTIC	1.29	1.31	1.55	-39.91	1812	ImClone Systems	IMCL	33	28.05	-15.00	-18.08	18664
Cellegy Pharma	CLGY	0.26	0.18	-30.77	-65.38	777	Immtech Intl	IMM	5.38	5.93	10.22	-14.55	255
CEL-SCI	CVM	0.79	0.64	-18.99	30.61	1376	Immucell	ICCC	4.99	4.97	-0.40	-5.33	7
Cephalon	CEPH	65.55	55.9	-14.72	-13.65	24391	ImmuCor	BLUD	19.86	19.02	-4.23	-18.58	2516
Cepheid	CPHD	9.2	7.44	-19.13	-15.26	3298	Immune Response	IMNR	0.02	0.02	0.00	-75.00	38053
Cerus	CERS	5.92	5.9	-0.34	-41.87	699	Immunicon	IMMC	3.99	4.62	15.79	34.69	255
Chelsea Thera	CHTP	3.49	3.75	7.45	33.45	17	ImmunoGen	IMGN	2.99	3.06	2.34	-40.35	283
Cholestech	CTEC	11.1	11.17	0.63	12.60	277	Immunomedics	IMMU	2	2.01	0.50	-31.16	387
Ciphergen	CIPH	0.96	0.98	2.08	-16.95	240	INCYTE	INCY	4.39	4.21	-4.10	-21.16	1240
Clearant	CLRI	0.5	0.46	-8.00	-78.30	553	Indevus Pharma	IDEV	5.47	5.64	3.11	4.83	2523
CollaGenex Pharma	CGPI	8.96	9.46	5.58	-21.62	643	Inhibitex	INHX	1.54	1.58	2.60	-81.19	336
Columbia Labs	CBRX	3.2	3.3	3.12	-29.03	175	Inovio Biomedical	INO	2.29	2.28	-0.44	0.44	184
CombiMatrix Group	CBMX	1.36	1.15	-15.44	-16.06	707	Insite Vision	ISV	1.5	1.57	4.67	89.16	1103
Compugen Ltd.	CGEN	2.94	2.55	-13.27	-40.14	67	Insmed	INSM	1.21	1.09	-9.92	-43.23	2257
Connetics	CNCT	10.39	10.02	-3.56	-30.66	2147	Inspire Pharma	ISPH	4.82	4.62	-4.15	-9.41	842
Corautus Genetics	VEGF	0.8	0.75	-6.25	-81.97	237	Integra LifeSci	IART	35.2	35.72	1.48	0.73	1054
Corcept Thera	CORT	3.66	3.97	8.47	8.77	323	Interleukin Genetics	ILI	5.84	6.02	3.08	12.52	187
Cortex Pharma	COR	2.78	2.78	0.00	21.93	123	InterMune	ITMN	15.81	15.52	-1.83	-7.40	2313
CoTherix	CTRX	7.41	6.33	-14.57	-40.17	800	IntraBiotics Pharma	IBPI	3.52	3.5	-0.57	-3.05	10
Critical Therapeut	CRTX	4.14	3.86	-6.76	-46.24	174	Introgen Thera	INGN	4	4	0.00	-24.10	467
Cruceel N.V.	CRXL	19.69	18.9	-4.01	-26.17	449	Invitrogen	IVGN	62.33	58.58	-6.02	-12.20	6029
Cubist Pharma	CBST	22.85	20.62	-9.76	-2.92	7136	ISIS Pharma	ISIS	6.59	6.35	-3.64	21.41	1377
CuraGen	CRGN	3.05	3.02	-0.98	-1.95	630	ISTA Pharma	ISTA	5.98	5.77	-3.51	-9.28	288
Curis	CRIS	1.09	0.99	-9.17	-72.11	1474	Javelin Pharma	JAV	3.89	3.8	-2.31	28.81	53
CV Therapeutics	CVTX	13	11	-15.38	-55.52	5567	Keryx Biopharma	KERX	11	10.18	-7.45	-30.46	2015
Cyanotech	CYAN	0.61	0.6	-1.64	-7.69	68	Kosan Biosciences	KOSN	3.46	3.13	-9.54	-29.19	160
Cyclacel Pharma	CYCC	6.2	5.24	-15.48	-21.79	8	La Jolla Pharma	LJPC	3.62	3.59	-0.83	-2.97	67
Cypress Bioscience	CYPB	5.7	5.66	-0.70	-2.08	808	Lexicon Genetics	LEXG	4.03	3.76	-6.70	3.01	635
Cytogen	CYTO	2.32	2.31	-0.43	-15.69	222	LifeCell Corporation	LIFC	29.07	27.48	-5.47	44.33	2445
Cytokinetics	CYTK	6.14	5.81	-5.37	-10.89	443	Lifecore Biomedical	LCBM	14.15	14.57	2.97	-10.17	257
CytRx	CYTR	1.13	1.1	-2.65	6.80	878	Ligand Pharma	LGND	9.2	8.42	-8.48	-24.48	1072
deCODE genetics	DCGN	5.04	5.03	-0.20	-39.10	1596	MacroChem	MACM	0.26	0.3	15.38	-64.29	25
Deltagen	DGEN	0.59	0.63	6.78	57.50	279	Manhattan Pharma	MHA	0.82	0.7	-14.63	-44.00	111

Company	Symbol	Close 8/4	Close 8/11	%Change WK	%Change YTD	Vol (000)	Company	Symbol	Close 8/4	Close 8/11	%Change WK	%Change YTD	Vol (000)
MannKind Corp	MNKD	18.48	15.57	-15.75	38.28	1781	Threshold Pharma	THLD	1.62	1.55	-4.32	-89.27	2627
Martek Biosciences	MATK	28.76	27.08	-5.84	9.90	1509	Titan Pharma	TTP	2.1	2	-4.76	-39.86	264
Matritech	MZT	0.76	0.6	-21.05	13.21	1364	Transgenomic	TBIO	0.44	0.39	-11.36	-63.21	491
Maxygen	MXY	7.49	7.65	2.14	2.00	201	Trimeris	TRMS	9.16	8.84	-3.49	-23.06	677
Medarex	MEDX	9.59	9.12	-4.90	-34.25	3918	Trinity Biotech plc	TRIB	8.01	8.04	0.37	-1.47	119
MedImmune	MEDI	26.12	25.83	-1.11	-26.16	11924	Tripes	TRPS	2.02	1.65	-18.32	-43.69	89
Memory Pharma	MEMY	1.06	1.05	-0.94	-53.95	885	Unigene	UGNE	2.42	2.38	-1.65	-46.03	931
Metabasis Thera	MBRX	6.47	5.59	-13.60	-30.13	202	United Therapeutics	UTHR	54.98	53.72	-2.29	-22.28	2052
MGI Pharma	MOGN	14	13.72	-2.00	-20.00	5322	Valentis	VLTS	0.39	0.34	-12.82	-84.11	1650
Micromet	MITI	2.94	2.9	-1.36	-29.95	62	VaxGen	VXGN	3.65	3.5	-4.11	-60.00	355
Millennium Pharma	MLNM	10.25	9.79	-4.49	0.93	18213	Vernalis plc ADS	VNLS	2.64	2.7	2.27	31.71	1
Miravant Medical	MRVT	0.02	0.02	0.00	-89.47	1503	Vertex Pharma	VRTX	32.7	30.44	-6.91	10.01	5375
Momenta Pharma	MNTA	17.15	14.75	-13.99	-33.08	1909	ViaCell	VIAC	3.71	3.75	1.08	-33.27	341
Monogram Biosci	MGRM	1.74	1.42	-18.39	-24.06	1795	Vical	VICL	4.74	4.97	4.85	18.33	389
Myogen	MYOG	30.72	30.9	0.59	2.69	2197	Vion Pharma	VION	1.01	1.04	2.97	-36.97	1833
Myriad Genetics	MYGN	25.1	25.34	0.96	21.89	1321	VioQuest Pharma	VQPH	0.8	0.79	-1.25	5.33	2
Nabi Biopharma	NABI	5.15	5.01	-2.72	47.35	1824	Viragen	VRA	0.27	0.27	0.00	-40.00	774
Nanogen	NGEN	1.92	1.8	-6.25	-31.03	962	ViroPharma	VPHM	8.71	8.41	-3.44	-54.54	5492
Nastech Pharma	NSTK	13.8	14.13	2.39	-3.94	821	Xenogen	XGEN	2.52	2.51	-0.40	-20.32	541
Nektar Therapeutics	NKTR	16.54	16.47	-0.42	0.06	6439	XenoPort	XNPT	17.52	17.88	2.05	-0.39	390
NeoPharm	NEOL	4.77	4.79	0.42	-55.61	413	XOMA Limited	XOMA	1.8	1.72	-4.44	7.50	2175
Neose Technologies	NEOC	2.55	2.23	-12.55	15.54	277	Ziopharm	ZIOP	4.9	4.9	0.00	50.77	59
Neurobio Techno	NTIL	2.89	2.75	-4.84	-23.40	100	ZymoGenetics	ZGEN	18.75	18.39	-1.92	8.24	1082
Neurochem Inc.	NRMX	10.79	9.88	-8.43	-30.96	1250							
Neurocrine Biosci	NBIX	9.11	9.09	-0.22	-85.51	3881							
Neurogen	NRGN	5.04	4.6	-8.73	-29.88	265							
New River Pharma	NRPH	22.31	22.98	3.00	-11.34	1080							
NitroMed	NTMD	2.83	2.95	4.24	-78.85	3116							
North American Sci	NASI	1.8	1.66	-7.78	-22.79	154							
Northfield Labs	NFLD	11.77	11.21	-4.76	-16.34	930							
Northwest Biothera	NWBT	0.17	0.18	5.88	80.00	330							
Novavax	NVAX	3.65	3.21	-12.05	-16.62	4355							
NPS Pharma	NPSP	3.91	3.72	-4.86	-68.58	1172							
Nuvelo	NUVO	16.35	16.46	0.67	102.96	2685							
Onyx Pharma	ONXX	16	13.44	-16.00	-53.33	7255							
OraSure Techno	OSUR	9.37	6.54	-30.20	-25.93	9146							
Orchid Biosciences	ORCH	2.38	2.34	-1.68	-69.41	954							
Ortec Intl.	OTCI	3.3	2.6	-21.21	-8.77	195							
Oscient Pharma	OSCI	1.07	1.19	11.21	-47.58	5740							
OSI Pharma	OSIP	34	34.09	0.26	21.58	7566							
Osteotech	OSTE	3.77	3.61	-4.24	-27.94	132							
OXIGENE	OXGN	3.41	3.21	-5.87	-19.14	295							
Oxis Intl.	OXIS	0.33	0.3	-9.09	15.38	111							
Pain Therapeutics	PTIE	8.8	8.82	0.23	30.47	1101							
Palatin Technol	PTN	2	2.32	16.00	-28.83	1531							
Peregrine Pharma	PPHM	1.38	1.25	-9.42	34.41	3891							
Pharma Drug Disc	PCOP	4.66	4.56	-2.15	28.09	126							
Pharma Prdt Dev	PPDI	37.94	37.54	-1.05	23.20	2074							
Pharmacyclics	PCYC	4.24	4.2	-0.94	18.31	170							
Pharmion	PHRM	16.94	16.42	-3.07	-7.60	1683							
Pharmos	PARS	1.87	1.75	-6.42	-12.94	121							
Pharsight	PHST	1.33	1.32	-0.75	-2.94	136							
Ponard Pharma	PARD	0.56	0.51	-8.93	-32.00	190							
Pracis Pharma	PRCS	2.48	2.15	-13.31	-46.25	133							
Progenics Pharma	PGNX	22.12	20.7	-6.42	-17.23	715							
Protein Design Labs	PDLI	17.23	17.55	1.86	-38.29	5264							
QLT Inc.	QLTI	7.14	7.07	-0.98	11.16	2277							
Questcor Pharma	QSC	1.76	1.75	-0.57	68.27	362							
Regeneration Tech	RTIX	5.76	5.25	-8.85	-26.57	447							
Regeneron Pharma	REGN	13.96	13.91	-0.36	-12.52	1457							
Renovis	RNVS	13.95	12.97	-7.03	-15.23	1151							
Repligen	RGEN	2.68	2.7	0.75	-32.50	444							
Repro Therapeut	RPRX	8.26	8.4	1.69	64.38	95							
Rigel Pharma	RIGL	9.93	8.99	-9.47	7.54	1134							
Salix Pharma	SLXP	10.41	11.13	6.92	-36.69	4325							
Sangamo Biosci	SGMO	5.08	4.49	-11.61	11.41	773							
Sanfarus	SNTS	5.3	5.97	12.64	12.64	3500							
Savient Pharma	SVNT	5.79	5.69	-1.73	52.14	2734							
SciClone Pharma	SCLN	2.07	2.04	-1.45	-12.07	354							
Seattle Genetics	SGEN	4.01	4	-0.25	-15.25	1039							
Senomyx	SNMX	13.57	13.59	0.15	12.13	601							
Sepracor	SEPR	49.97	48.34	-3.26	-6.32	9479							
Sequenom	SQNM	1.63	1.85	13.50	-9.31	196							
Serono S.A.	SRA	16.64	16.75	0.66	-15.66	672							
SIGA Technologies	SIGA	1.15	1.13	-1.74	18.95	55							
Simulations Plus	SLP	5.5	5.84	6.18	12.74	49							
Sirna Therapeutics	RNAI	5.12	4.58	-10.55	51.16	1826							
Solexa	SLXA	9.02	8.65	-4.10	-14.10	1186							
Sonus Pharma	SNUS	4.89	4.68	-4.29	-6.96	237							
Spectrum Pharma	SPPI	3.58	3.58	0.00	-15.37	1178							
StemCells	STEM	2.18	2.04	-6.42	-40.87	2491							
Stratagene	STGN	6.93	6.14	-11.40	-38.84	209							
SuperGen	SUPG	3.35	3.11	-7.16	-38.42	1379							
Tanox	TNOX	14.54	14.14	-2.75	-13.62	1091							
Tapestry Pharma	TPPH	2.78	2.57	-7.55	-17.10	41							
Targeted Genetics	TGEN	2	1.77	-11.50	-63.88	47							
Telik	TELK	16.54	15.55	-5.99	-8.48	2607							
Tercica	TRCA	5.18	5.13	-0.97	-28.45	588							
Theravance	THRX	23.5	25.44	8.26	12.97	1325							
Third Wave Techno	TWTI	3	3.33	11.00	11.74	811							

**LONDON STOCK EXCHANGE**

Company	Symbol	8/4	8/11	%WK	%YTD	Volume
Acambis	ACM	132	128.75	-2.46	-38.32	930
Antisoma	ASM	13.5	14.4	6.67	-25.77	3174
Ark Therapeutics	AKT	77	79.5	3.25	-22.82	687
Asterand	ATD	6.25	6.9	10.40	-54.00	20
Cambridge Antibdy	CAT	1319	1319	0.00	88.97	0
Oxford Biomedica	OXB	23.75	24.25	2.11	-19.83	4156
Phytopharm	PYM	55.5	53.25	-4.05	0.47	421
Protherics	PTI	78	80.25	2.88	-3.02	1555
Provalis	PRO	0.7	0.29	-58.57	-82.94	7484
SkyePharma	SKP	24	24.25	1.04	-51.98	24912
Vernalis plc	VER	67.25	66	-1.86	8.20	869

Note: Prices are denoted in pence.

**TORONTO STOCK EXCHANGE**

Company	Symbol	8/4	8/11	%WK	%YTD	Volume
Adherex Techno	AHX	0.55	0.37	-32.73	-61.46	183
Allon Therapeutics	NPC	1	1	0.00	17.65	19
Angiotech Pharma	ANP	13.36	12.13	-9.21	-20.93	1029
AnorMED	AOM	6.72	6.55	-2.53	37.32	135
Bioms Medical	MS	3.45	3.4	-1.45	34.92	63
Bioniche Life Sci	BNC	0.68	0.66	-2.94	-5.71	112
Cangene	CNJ	8.6	8.41	-2.21	-17.55	17
Cardiome Pharma	COM	13.61	13.37	-1.76	14.08	686
Chromos Mlcr Sys	CHR	0.18	0.19	5.56	18.75	2
ConjuChem Biotech	CJB	1.27	1.31	3.15	20.18	606
Ecoxia Biosciences	EIA	0.28	0.26	-7.14	-52.73	68
Hemosol	HML	0.15	0.12	-20.00	50.00	138
IBEX Techno	IBT	0.17	0.16	-5.88	-44.83	8
Inex Pharma	IEX	0.3	0.28	-6.67	-3.45	245
Inflazyme Pharma	IZP	0.13	0.13	0.00	8.33	1167
Lorus Therapeut	LOR	0.32	0.31	-3.13	0.00	391
Medicure	MPH	1.72	1.79	4.07	14.74	814
Neurochem	NRM	12.2	11.24	-7.87	-32.25	814
Nventa Biopharma	NVN	0.29	0.27	-6.90	-51.79	597
Oncolytics Biotech	ONC	2.6	2.6	0.00	-50.38	164
Resverlogix	RVX	5.63	5.1	-9.41	-25.00	98
Theratechnologies	TH	1.53	1.56	1.96	45.79	137
Wex Pharma	WXI	0.35	0.33	-5.71	-71.55	178
YM Biosciences	YM	3.6	3.17	-11.94	-13.39	412

Note: Prices are denoted in Canadian dollars.

**NOTES:**

Trading volumes for Nasdaq, Amex and NYSE are recorded as the total number of shares traded (in thousands) on a weekly basis (cumulative Monday through Friday); the weekly and YTD % changes are from IPO completion, where applicable.

**Average Percent Change Week: -3.67%**

Range: -7